Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03044613 · ClinicalTrials.gov registry record · Phase 1

Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer

A Phase 1 study of Gastric Cancer and Esophageal Cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Active
Registry status
Phase 1
Development phase
32
Enrollment target
3
Study locations

NCT03044613: Active Phase 1 study of Gastric Cancer and Esophageal Cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

NCT03044613 is a Phase 1 study of Gastric Cancer and Esophageal Cancer that is active but no longer recruiting, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 32 participants, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (90% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03044613, a Phase 1 study of Gastric Cancer and Esophageal Cancer, is active but no longer recruiting, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
32 participants
Enrollment target
3
Study locations

Study Summary

Anti-PD-1 (nivolumab) or Anti-PD1/Anti LAG-3- (relaltimab) administration in the pre-operative setting with chemoradiation will be safe and feasible in patients with resectable distal esophageal/gastroesophageal junction cancer and will change cellular and molecular characteristics of the tumor microenvironment that will improve survival.

Primary Outcome

To investigate the safety of induction nivolumab or nivolumab/relatlimab administration prior to concurrent chemoradiation and nivolumab or nivolumab/relatlimab in subjects with resectable stage II/III gastro-esophageal junction cancer.

Conditions Studied

Gastric Cancer Esophageal Cancer GastroEsophageal Cancer

Interventions

  • DRUG Carboplatin
  • DRUG Nivolumab
  • DRUG Relatlimab
  • DRUG Paclitaxel
  • RADIATION Radiation

Study Locations (3)

Maryland

  • Johns Hopkins University - Baltimore

Pennsylvania

  • Alleghany Health Network - Pittsburgh

Texas

  • Baylor University/ Charles A. Sammons Cancer Center - Dallas

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2017-07-11
Est. Completion 2027-08
Phase Phase 1
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

523 total trials

What the registry record for NCT03044613 still lists

NCT03044613 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (90% lower).

The record links to 3 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.

NCT03044613 reports a single indexed study location in Maryland, Pennsylvania, Texas.

Frequently Asked Questions

What is clinical trial NCT03044613 about?

NCT03044613 is a clinical study titled "Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer". Anti-PD-1 (nivolumab) or Anti-PD1/Anti LAG-3- (relaltimab) administration in the pre-operative setting with chemoradiation will be safe and feasible in patients with resectable distal esophageal/gastroesophageal junction cancer and will change cellular and molecular characteristics of the tumor micr...

What is the current status of trial NCT03044613?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2017-07-11. Estimated completion is 2027-08.

What conditions does trial NCT03044613 study?

This clinical trial studies the following conditions: Gastric Cancer, Esophageal Cancer, GastroEsophageal Cancer.

What interventions are being tested in trial NCT03044613?

The interventions under investigation include: Carboplatin (DRUG), Nivolumab (DRUG), Relatlimab (DRUG), Paclitaxel (DRUG), Radiation (RADIATION).

Who is sponsoring clinical trial NCT03044613?

This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03044613 being conducted?

This trial has 3 study locations across Maryland, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gastric Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03044613's enrollment target sits among peer trials

32 137th of 153 higher than 16 of 153 other Gastric Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Gastric Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02445781 · 32 participants · Early Phase 1

    Differing Levels of Hypoglycemia

  • NCT02792270 · 32 participants · NA

    Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT

  • NCT03068910 · 32 participants · Early Phase 1

    Hyperandrogenemia and Altered Day-night LH Pulse Patterns

  • NCT03208868 · 32 participants · NA

    Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03044613, the US trial registry maintained by the National Library of Medicine. NCT03044613 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.